Cargando…

Heteroaromatic ester inhibitors of hepatitis A virus 3C proteinase: Evaluation of mode of action

The related 3C and 3C-like proteinase (3C(pro) and 3CL(pro)) of picornaviruses and coronaviruses, respectively, are good drug targets. As part of an effort to generate broad-spectrum inhibitors of these enzymes, we screened a library of inhibitors based on a halopyridinyl ester from a previous study...

Descripción completa

Detalles Bibliográficos
Autores principales: Huitema, Carly, Zhang, Jianmin, Yin, Jiang, James, Michael N.G., Vederas, John C., Eltis, Lindsay D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd. 2008
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7125897/
https://www.ncbi.nlm.nih.gov/pubmed/18407505
http://dx.doi.org/10.1016/j.bmc.2008.03.059
_version_ 1783516043011948544
author Huitema, Carly
Zhang, Jianmin
Yin, Jiang
James, Michael N.G.
Vederas, John C.
Eltis, Lindsay D.
author_facet Huitema, Carly
Zhang, Jianmin
Yin, Jiang
James, Michael N.G.
Vederas, John C.
Eltis, Lindsay D.
author_sort Huitema, Carly
collection PubMed
description The related 3C and 3C-like proteinase (3C(pro) and 3CL(pro)) of picornaviruses and coronaviruses, respectively, are good drug targets. As part of an effort to generate broad-spectrum inhibitors of these enzymes, we screened a library of inhibitors based on a halopyridinyl ester from a previous study of the severe acute respiratory syndrome (SARS) 3CL proteinase against Hepatitis A virus (HAV) 3C(pro). Three of the compounds, which also had furan rings, inhibited the cleavage activity of HAV 3C(pro) with K(ic)s of 120–240 nM. HPLC-based assays revealed that the inhibitors were slowly hydrolyzed by both HAV 3C(pro) and SARS 3CL(pro), confirming the identity of the expected products. Mass spectrometric analyses indicated that this hydrolysis proceeded via an acyl-enzyme intermediate. Modeling studies indicated that the halopyridinyl moiety of the inhibitor fits tightly into the S1-binding pocket, consistent with the lack of tolerance of the inhibitors to modification in this portion of the molecule. These compounds are among the most potent non-peptidic inhibitors reported to date against a 3C(pro).
format Online
Article
Text
id pubmed-7125897
institution National Center for Biotechnology Information
language English
publishDate 2008
publisher Elsevier Ltd.
record_format MEDLINE/PubMed
spelling pubmed-71258972020-04-08 Heteroaromatic ester inhibitors of hepatitis A virus 3C proteinase: Evaluation of mode of action Huitema, Carly Zhang, Jianmin Yin, Jiang James, Michael N.G. Vederas, John C. Eltis, Lindsay D. Bioorg Med Chem Article The related 3C and 3C-like proteinase (3C(pro) and 3CL(pro)) of picornaviruses and coronaviruses, respectively, are good drug targets. As part of an effort to generate broad-spectrum inhibitors of these enzymes, we screened a library of inhibitors based on a halopyridinyl ester from a previous study of the severe acute respiratory syndrome (SARS) 3CL proteinase against Hepatitis A virus (HAV) 3C(pro). Three of the compounds, which also had furan rings, inhibited the cleavage activity of HAV 3C(pro) with K(ic)s of 120–240 nM. HPLC-based assays revealed that the inhibitors were slowly hydrolyzed by both HAV 3C(pro) and SARS 3CL(pro), confirming the identity of the expected products. Mass spectrometric analyses indicated that this hydrolysis proceeded via an acyl-enzyme intermediate. Modeling studies indicated that the halopyridinyl moiety of the inhibitor fits tightly into the S1-binding pocket, consistent with the lack of tolerance of the inhibitors to modification in this portion of the molecule. These compounds are among the most potent non-peptidic inhibitors reported to date against a 3C(pro). Elsevier Ltd. 2008-05-15 2008-03-27 /pmc/articles/PMC7125897/ /pubmed/18407505 http://dx.doi.org/10.1016/j.bmc.2008.03.059 Text en Copyright © 2008 Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Huitema, Carly
Zhang, Jianmin
Yin, Jiang
James, Michael N.G.
Vederas, John C.
Eltis, Lindsay D.
Heteroaromatic ester inhibitors of hepatitis A virus 3C proteinase: Evaluation of mode of action
title Heteroaromatic ester inhibitors of hepatitis A virus 3C proteinase: Evaluation of mode of action
title_full Heteroaromatic ester inhibitors of hepatitis A virus 3C proteinase: Evaluation of mode of action
title_fullStr Heteroaromatic ester inhibitors of hepatitis A virus 3C proteinase: Evaluation of mode of action
title_full_unstemmed Heteroaromatic ester inhibitors of hepatitis A virus 3C proteinase: Evaluation of mode of action
title_short Heteroaromatic ester inhibitors of hepatitis A virus 3C proteinase: Evaluation of mode of action
title_sort heteroaromatic ester inhibitors of hepatitis a virus 3c proteinase: evaluation of mode of action
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7125897/
https://www.ncbi.nlm.nih.gov/pubmed/18407505
http://dx.doi.org/10.1016/j.bmc.2008.03.059
work_keys_str_mv AT huitemacarly heteroaromaticesterinhibitorsofhepatitisavirus3cproteinaseevaluationofmodeofaction
AT zhangjianmin heteroaromaticesterinhibitorsofhepatitisavirus3cproteinaseevaluationofmodeofaction
AT yinjiang heteroaromaticesterinhibitorsofhepatitisavirus3cproteinaseevaluationofmodeofaction
AT jamesmichaelng heteroaromaticesterinhibitorsofhepatitisavirus3cproteinaseevaluationofmodeofaction
AT vederasjohnc heteroaromaticesterinhibitorsofhepatitisavirus3cproteinaseevaluationofmodeofaction
AT eltislindsayd heteroaromaticesterinhibitorsofhepatitisavirus3cproteinaseevaluationofmodeofaction